Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Celldex Therapeutics, Inc.

Filed: Apr 1, 2026CIK: 0000744218
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Celldex Therapeutics raised $282 million through a public offering of 10.3 million shares at $29 per share on April 1, 2026. This significant capital raise strengthens the company's balance sheet and provides funding for strategic operations and future initiatives.

Key Takeaways

Celldex sold 10,345,000 shares of common stock at $29.00 per share in a public offering

Net proceeds of approximately $282 million after underwriting discounts and expenses

3 more takeaways

Filing Overview

Form Type8-K
Filing DateApr 1, 2026
Item1.01
CategoryMaterial Agreement
CIK0000744218
Accession #0000744218
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings